Finter F, Mottaghy F M, Kuefer R, Hautmann R E, Rinnab L
Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, 89075, Ulm.
Urologe A. 2007 Aug;46(8):904, 906-12. doi: 10.1007/s00120-007-1521-4.
Bone metastases develop commonly in patients with a variety of urogenital malignancies and are a major cause of morbidity and diminished quality of life in a significant proportion of urogenital carcinoma patients. For example, bone metastases occur in approximately 80% of patients with hormone-refractory prostate cancer and in approximately 25% of patients with renal cell carcinoma. A sufficient and early therapy is crucial since adequate therapy can lead to significant improvements in pain control and function and maintain skeletal integrity. The effective treatment of bone metastases requires multidisciplinary cooperation between urologists, oncologists, surgeons, nuclear medicine physicians and radiation oncologists. Analgesic measures, bisphosphonates, radionuclides, radiation therapy as well as surgical procedures are available. This review will focus mainly on the role of analgetics, bisphosphonates, radionuclides and radiolabelled bisphosphonates in the treatment of bone metastases.
骨转移在各种泌尿生殖系统恶性肿瘤患者中很常见，并且是相当一部分泌尿生殖系统癌症患者发病和生活质量下降的主要原因。例如，约80%的激素难治性前列腺癌患者会发生骨转移，约25%的肾细胞癌患者会发生骨转移。充分且早期的治疗至关重要，因为适当的治疗可显著改善疼痛控制和功能，并维持骨骼完整性。骨转移的有效治疗需要泌尿科医生、肿瘤学家、外科医生、核医学医生和放射肿瘤学家之间的多学科合作。有止痛措施、双膦酸盐、放射性核素、放射治疗以及外科手术等治疗手段。本综述将主要关注镇痛药、双膦酸盐、放射性核素和放射性标记双膦酸盐在骨转移治疗中的作用。
